[ad_1] MUNICH (Reuters) – An AstraZeneca drug blocking the ability of a cancer cell to repair its genetic code has significantly reduced the risk of ovarian cancer worsening in a phase III …
Read More »Lynparza of AstraZeneca has demonstrated its effectiveness in curbing ovarian cancer
